Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mogrol** is a naturally occurring tetracyclic triterpenoid and the aglycone (non-sugar part) of mogrosides, primarily derived from *Siraitia grosvenorii* (monk fruit), widely used in traditional Chinese medicine and as a natural sweetener source[1][3][5]. Mogrol is formed in the body from mogrosides after oral ingestion by deglycosylation through gastrointestinal enzymes and microbiota[1][3].\nMogrol exhibits multiple pharmacological effects, including:\n- **Activation of AMP-activated protein kinase (AMPK)**, leading to anti-obesity, anti-inflammatory, and anti-diabetes activity\n- **Inhibition of ERK1/2 and STAT3 pathways** (anticancer effect, including inhibition of leukemia and lung cancer cell proliferation)\n- **Inhibition of CREB activation** (reducing adipogenesis)\n- **Neuroprotective effects** (inhibition of NF-κB pathway)\n- **Suppression of osteoclast formation and bone resorption** (potential anti-osteoporosis effect through inhibition of TRAF6 recruitment and MAPK/NF-κB signaling)\n- Potential alleviation of inflammatory conditions (e.g., ulcerative colitis) via inhibition of inflammatory mediator production[3][5][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mogrol.